Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sequana Medical NV

Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
From Sequana Medical NV
Via GlobeNewswire
Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024
From Sequana Medical NV
Via GlobeNewswire
Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®
From Sequana Medical NV
Via GlobeNewswire
Transparency Notifications from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Strong data from DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
From Sequana Medical NV
Via GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy
From Sequana Medical NV
Via GlobeNewswire
Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis
From Sequana Medical NV
Via GlobeNewswire
Transparency Notifications from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
From Sequana Medical NV
Via GlobeNewswire
Transparency Notifications from Shareholders
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical granted US CPT® III reimbursement codes for alfapump® system
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces H1 2023 results and provides business update
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical Notice of 2023 Half-year Results and Business Update
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
From Sequana Medical NV
Via GlobeNewswire
1,000th alfapump® implant completed
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces results of Special General Meeting of Shareholders
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
From Sequana Medical NV
Via GlobeNewswire
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
From Sequana Medical NV
Via GlobeNewswire
Sequana Medical announces results of Annual General Meeting of Shareholders
From Sequana Medical NV
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.